It’s too early to say what Pfizer’s bid for AstraZeneca means for MedImmune. But it’s starting to become clearer what MedImmune means for Pfizer’s bid for AstraZeneca.
As Pfizer courts MedImmune’s U.K.-based parent, one promising immunotherapy product — MEDI4736, now in late-stage clinical trials for non-small cell lung cancer — has seen a flood of attention alongside another closely watched lung cancer drug, AZD9291. Data on both drugs are slated to be presented at the end of May at the American Society of Clinical Oncology’s annual conference in Chicago. AstraZeneca is looking to wield positive results to showcase its immuno-oncology pipeline, undergirding the argument that it’s worth more than the $106 billion that Pfizer originally bid for it.